Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Is Allergan a Buy?

You might think it's too late to profit with this soon-to-be-acquired drug stock. Think again.

The 10 Biggest Healthcare Stocks

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

Is Editas Medicine a Buy?

High risk? Definitely. But this small biotech also has the potential for high returns over the long run.